CNTB
NASDAQ · Biotechnology
Connect Biopharma Holdings L
$2.43
+0.13 (+5.65%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 69.44M | 70.73M | 65.75M |
| Net Income | 4.31M | 5.04M | 3.90M |
| EPS | — | — | — |
| Profit Margin | 6.2% | 7.1% | 5.9% |
| Rev Growth | +2.8% | -4.7% | +21.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 72.52M | 64.29M | 59.58M |
| Total Equity | 80.64M | 74.11M | 84.59M |
| D/E Ratio | 0.90 | 0.87 | 0.70 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.85M | 6.49M | 5.56M |
| Free Cash Flow | 3.99M | 3.58M | 4.07M |